Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent - Full Text View

Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent

This study is currently recruiting participants.
Verified by University of Alabama at Birmingham, April 2007

Sponsors and Collaborators:	University of Alabama at Birmingham Genentech
Information provided by:	University of Alabama at Birmingham
ClinicalTrials.gov Identifier:	NCT00334945

Purpose

The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormone treatment improves bone density and bone mineral content. The amount of phosphorus is maintained by the kidneys. Fibroblast 23 has recently been recognized to help kidneys control phosphate levels.

Condition

Growth Disorders

MedlinePlus related topics:

Growth Disorders

ChemIDplus related topics:

Somatotropin Somatropin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Longitudinal, Case Control, Prospective Study

Official Title:	Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent)

Further study details as provided by University of Alabama at Birmingham:

Estimated Enrollment:	35
Study Start Date:	April 2006

Eligibility

Ages Eligible for Study:	3 Years to 14 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Twenty children with significant short stature < 3rd percentile, ages 3-14 years, and referred to Children's Hospital of Alabama
Normal healthy volunteer children 3-18 years with normal stature

Exclusion Criteria:

Patients on medication including GH
Patients with concomitant hormonal abnormalities
Patients with disorders of calcium and phosphate metabolism
Active neoplasms
Closed epiphysis
Known bone disorders

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334945

Contacts


Contact: Tammi L Skelton, RN, BSN	205-939-9107	tskelton@peds.uab.edu

Locations


United States, Alabama
	Children's Hospital of Alabama	Recruiting
	Birmingham, Alabama, United States, 35233

Sponsors and Collaborators

University of Alabama at Birmingham

Genentech

Investigators


Principal Investigator:	Kenneth L McCormick, MD	University of Alabama at Birmingham

More Information

Study ID Numbers:	X041104010, X3395n
First Received:	June 7, 2006
Last Updated:	April 24, 2007
ClinicalTrials.gov Identifier:	NCT00334945
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:

Fibroblast Growth Factors

Bone development

Study placed in the following topic categories:

Growth Disorders

Additional relevant MeSH terms:

Pathologic Processes

ClinicalTrials.gov processed this record on October 14, 2008